Abstract
AbstractBackgroundPharmacological treatment for AD and depression are unfortunately few and of limited efficacy to cure the disease.MethodLongitudinal clinical prospective study with 1278 AD patients on rivastigmine 9,5mg/patch and citalopram 20‐40 mg/day over 48 months was assessed on the basis of NINCDS‐ADRDA, MMSE, DSM‐IV, FRSSD, GDS, HRS‐D and follow up of the patients.ResultFour years after the baseline assessment, there were no significant differences in MMSE, Geriatric depression scale and Hamilton rating scale for depression between patients treated with rivastigmine alone or combined rivastigmine with citalopram with or without depression (p>0.05). Functional Rating Scale for symptoms of dementia, Activities of Daily Living of patients with AD and depression treated with rivastigmine was significantly worse than patients treated with rivastigmine and no depression (p=0.027).ConclusionThe combination of rivastigmine and citalopram had no better results than rivastigmine alone in patients with AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
